期刊文献+

PETIA法检测血清半胱氨酸蛋白酶抑制剂C方法学评价 被引量:2

下载PDF
导出
摘要 目的对颗粒增强透射免疫比浊法(PETIA)测定血清半胱氨酸蛋白酶抑制剂C(Cys C)进行方法学评价。方法根据美国临床实验室标准化委员会(NCCLS)EP5-A、EP6-A、EP9-A及EP7-P文件对PETIA测定血清Cys C的精密度、可报告范围、方法学比较及干扰实验进行评价和比较。结果PETIA的低水平样本批内变异系数(CV)为1.34%、批间CV为2.19%、日间CV为1.82%、总CV为2.56%;高水平样本批内CV为1.15%、批间CV为1.40%、日间CV为2.23%、总CV为2.58%。可报告范围为0.44-4.46 mg/L。PETIA与颗粒增强散射免疫比浊法(PENIA)呈显著相关[决定系数(r^2)=0.997 2,P〈0.01]。血红蛋白(Hb)〈5 g/L、三酰甘油(TG)〈12 mmol/L、总胆红素(TB il)〈150μmol/L时,PETIA测定Cys C高、低水平样本的干扰值均在干扰限度值(1.96s)范围内。结论PENIA具有良好的重复性,与PENIA有良好的相关性,抗干扰能力较强。因此PETIA是测定血清Cys C较理想的方法,可应用于临床检测。
出处 《检验医学》 CAS 北大核心 2010年第3期233-235,共3页 Laboratory Medicine
  • 相关文献

参考文献8

  • 1Kyhse-Andersen J, Schmidt C, Nordin G, et al. Serum cystain C, determined by a rapid, automated particle- enhanced turbidimetric method,is a better marker than serum creatinine for glomerular filtration rate [ J ]. Clin Chem, 1994,40(10) : 1921-1926.
  • 2National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices[ S]. NCCLS, EP5-A,1999.
  • 3National Committee for Clinical Laboratory Standards. Evaluation of the linearity of quantitative analytical methods[ S]. NCCLS, EP6-A, 1986.
  • 4National Committee for Clinical Laboratory Standards. Method comparison and bias estimation using patient samples[S]. NCCLS, EP9-A, 1995.
  • 5National Committee for Clinical Laboratory Standards. Interference testing in clinical chemistry[S]. NCCLS, EP7-P, 1986.
  • 6李萍,赵莹,黄亨健,彭志英,徐克和.胱蛋白酶抑制剂C对肾小球滤过功能的评价[J].中华检验医学杂志,2005,28(5):515-516. 被引量:29
  • 7顾国琴,白亚玲.血清半胱氨酸蛋白酶抑制剂C的测定方法及临床应用[J].中华检验医学杂志,2007,30(8):952-954. 被引量:23
  • 8Finney H, Newman DJ, Gruber W, et al. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems( BNA,BN Ⅱ) [ J]. Clin Chem, 1997,43 (6 Pt 1 ) : 1016-1022.

二级参考文献36

  • 1李海霞,张春丽,徐国宾,王学晶,李淑葵,李志艳,张旭初,夏铁安.健康人群血清半胱氨酸蛋白酶抑制剂C与肌酐分布及其评价慢性肾脏病患者肾小球滤过功能的比较研究[J].中华检验医学杂志,2006,29(11):970-974. 被引量:179
  • 2艾洪武,陈莎,邱艳,孙红,游上游.血清γ-痕迹蛋白在儿童肾脏疾病中的应用价值[J].临床儿科杂志,2006,24(12):987-989. 被引量:2
  • 3Abrahamson M,Mason RW,Hansson H,et al. Human cystatin C.role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leucocyte elastase. Biochem J, 1991,273:621-626.
  • 4Grubb A.Diagnostic value of analysis of cystatin and protein HC in biological fluids.Clin Nephol,1992,38 suppl 1:S 20-27
  • 5Ekiel I,Abrahamson M,Fulton DB,et al. NMR Structural studies of human cystatin C dimmers and monomers. J Mol Biol, 1997,271:266-277.
  • 6Thielemans N, Lauwerys R, Bernard A. Competition between albumin and low-molecular-weight protein for renal tubular uptake in experimental nephropathies. Nephron, 1994, 66:453-458.
  • 7Joronen I,Hopsu-Havu VK,Rinne A,et al. Detection of low molecular weight cysteine proteinase inhibitors by time-resolved fluoroimmunoassay. J Immunal Meth, 1986,86:243-247.
  • 8Colle A,Tavera C,Prevot D,et al. Cystatin C levels in sera of patein with human immunodeficiency virus infection. J immunoassay,1992,13:47-60.
  • 9Newman DJ.Cystatin C. Ann Clin biochem,2002,39:89-104.
  • 10Fanos V,Mussap M,Plebani M,et al. Cystatin C in paediatric nephrology, present situation and propect. Minerva Pediatr,1999,51:167-177.

共引文献49

同被引文献35

  • 1Conde-Sánchez M,Roldán-Fontana E,Chueca-PorcunaN,et al.Analytical performance evaluation of aparticle-enhanced turbidimetric cystatin C assay onthe Roche COBAS 6000 analyzer[J].Clin Biochem,2010,43(10-11):921-925.
  • 2Seegmiller JC,Sviridov D,Larson TS,et al.Comparisonof urinary albumin quantification by immunoturbidimetry,competitive immunoassay,and protein-cleavage liquidchromatography-tandem mass spectrometry[J].ClinChem,2009,55(11):1991-1994.
  • 3Dupuy AM,Debarge L,Poulain M,et al.Determinationof serum ferritin using immunoturbidimetry orchemiluminescent detection in comparison withradioimmunoassay a compendium of a methodologicaljuxtaposition[J].Clin Lab,2009,55(5-6):207-215.
  • 4Jones TG,Warber KD,Roberts BD.Analysis ofhemoglobin A1c from dried blood spot samples withthe Tina-quantRⅡimmunoturbidimetric method[J].J Diabetes Sci Technol,2010,4(2):244-249.
  • 5Shaikh A,Seegmiller JC,Borland TM,et al.Comparisonbetween immunoturbidimetry,size-exclusion chromato-graphy,and LC-MS to quantify urinary albumin[J].Clin Chem,2008,54(9):1504-1510.
  • 6Al-Turkmani MR,Law T,Kellogg MD.Performanceevaluation of a particle-enhanced turbidimetriccystatin C assay on the Hitachi 917 analyzer[J].Clin Chim Acta,2008,398(1-2):75-77.
  • 7Tugirimana PL,Holderbeke AL,Kint JA,et al.A newturbidimetric method for assaying serum C-reactiveprotein based on phosphocholine interaction[J].ClinChem Lab Med,2009,47(11):1417-1422.
  • 8Hansson LO,Grubb A,Lidén A,et al.Performanceevaluation of a turbidimetric cystatin C assay ondifferent high-throughput platforms[J].Scand J ClinLab Invest,2010,70(5):347-353.
  • 9Ledue TB,Collins MF,Ritchie RF.Development ofimmunoturbidimetric assays for fourteen human serumproteins on the Hitachi 912[J].Clin Chem LabMed,2002,40(5):520-528.
  • 10Mali B,Armbruster D,Serediak E,et al.Comparisonof immunoturbidimetric and immunonephelometricassays for specific proteins[J].Clin Biochem,2009,42(15):1568-1571.

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部